TP53 and non-small cell lung carcinoma: Among currently untargetable genomic alterations, there were higher frequencies of TP53 (70% vs. 63%, p < 0.0001) and RB1 inactivation (10% vs. 2%, p < 0.0001) in the MTAP‐intact NSCLC cohort and a higher frequency of SMARCA4 inactivation (7 vs. 10%, p < 0.0001) in the MTAP‐loss NSCLC cohort.